Biogen (BIIB) PT Lowered to $213 at RBC Capital
Get Alerts BIIB Hot Sheet
Price: $214.35 --0%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 17
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 17
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $213.00 (from $233.00) while maintaining a rating.
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
- FLSmidth & Co A/S (FLS:DC) (FLIDF) PT Raised to DKK600 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share